Category Archives: People

BioSyent Declares Second Quarter 2026 Dividend

MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on June 15, 2026, to shareholders of record at the close of business on May 29, […]

Solésence Supports Landmark Report on UV Safety in the United Kingdom as Member of UV Safety Coalition

The report, led by the United Kingdom’s APPG for Beauty, Hair & Wellbeing, calls for a national strategy to combat UV exposure, including Government support to enable access to adequate protection, build public awareness and combat misinformation. From left the photo includes: Carolyn Harris, MP, Chair of the APPG for Beauty, Hair & Wellbeing, Victoria […]

BioSyent Releases Financial Results for First Quarter 2026

MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the first quarter (Q1) ended March 31, 2026. Key highlights include: (CAD) Q1 2026 % Change vs.Q1 2025 TTMMar 31, 2026 % Change vs.TTMMar 31, 2025 Pharmaceutical Sales 10,803,107 +1% 40,987,981 +11% Oral Health Sales […]

Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology Company targeting U.S. clinical trial launch in second half of 2026 Peer-Reviewed Studies published in The Journal of Diabetes Research and in the Institute of Electrical […]

LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update

BOCA RATON, Fla., May 14, 2026 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission (“SEC”) for the first quarter ended […]

Aveanna Healthcare Holdings Announces First Quarter Financial Results and Revised 2026 Guidance

First Quarter Revenue was $647.9 million, a 15.9% increase over the prior year period First Quarter Net income was $41.7 million compared to $5.2 million for the prior year period Adjusted EBITDA for Q1 2026 was $84.4 million, a 25.2% increase over the prior year period Increased Full Year 2026 Revenue guidance to between $2.56 […]

Prenetics Welcomes Brian J. Rosin as Chief Financial Officer of IM8

~ Two-decade veteran of premium consumer health, nutrition, and direct-to-consumer brands joins IM8 to support its rapid global expansion NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) — Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced the appointment […]

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026 Announced purpose-built commercial partnership with EVERSANA® to support potential U.S. launch of aglatimagene in localized prostate cancer Company reported extended survival tail observed in trial of aglatimagene in advanced non-small […]

Koelis Announces ProMap® Smart Automatic Prostate Contouring Software at AUA 2026

PRINCETON, N.J., May 14, 2026 (GLOBE NEWSWIRE) — Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a global leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, announced today the official launch of its new software ProMap® Smart at the prestigious American Urological Association (AUA) Annual Meeting in Washington, DC. Designed to optimize the […]

INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer’s Disease

BOCA RATON, FL, May 14, 2026 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to XPro™ (pegipanermin), the company’s first-in-class selective soluble TNF inhibitor, for the treatment of early Alzheimer’s disease […]